MedTrace Logo

Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors

NCT03381014 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-12-21

No results posted yet for this study

Summary

Early detection of cardiomyopathy in patients receiving Anthracycline chemotherapy and determine if speckle tracking echo and Troponin gene will add benefit for early detection of cardiomyopathy.

Improve economic impact of oncologic patients from whom high sensitive troponin negative and normal speckle tracking patients can be safely excluded from long-term cardiac monitoring programs.

To correlate between the molecular gene expression of troponin genes and ryanodine receptor in cardiomyopathy

Conditions

  • Chemotherapy Effect

Interventions

DRUG

Chemotherapy, Cancer, Anthracyclines

follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • yehia T kishk, MD · cardiology department

  • Mohamed K Koriem, MD · cardiology department

  • Naglaa K Idriss, MD · biochemistry department

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2019-01-01
Completion
2019-08-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03381014 on ClinicalTrials.gov